Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a

Rijckborst, Vincent; Hansen, Bettina; Ferenci, Peter; Brunetto, Maurizia; Tabak, Ömer; Cakaloglu, Yilmaz; Lanza, A.; Messina, Vincenzo; Iannacone, Claudio; Massetto, Benedetta; Regep, Loredana; Colombo, Massimo; Janssen, Harry; Lampertico, Pietro

doi:10.1016/j.jhep.2011.12.007

Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a

Copy For Citation

Rijckborst V., Hansen B. E., Ferenci P., Brunetto M. R., Tabak F., Cakaloglu Y., ...More

JOURNAL OF HEPATOLOGY, vol.56, no.5, pp.1006-1011, 2012 (SCI-Expanded)

Publication Type: Article / Article
Volume: 56 Issue: 5
Publication Date: 2012
Doi Number: 10.1016/j.jhep.2011.12.007
Journal Name: JOURNAL OF HEPATOLOGY
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.1006-1011
Istanbul University Affiliated: Yes

Abstract

Background & Aims: It was recently demonstrated that none of the hepatitis B e antigen (HBeAg)-negative patients without any serum hepatitis B surface antigen (HBsAg) decline and with <2 log hepatitis B virus (HBV) DNA decline at week 12 of a 48-week peginterferon alfa-2a (PEG-IFN) treatment course achieved a sustained response (SR). We aimed at validating this stopping rule in two independent trials.